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Abstract
Background: Cancer of unknown primary (CUP) is a heterogeneous group of cancers, so called when a biopsy from a patient
reveals malignancy without giving a clue to where in the body the primary tumor is located. Whole-body 18-ﬂuorine-
ﬂuorodeoxyglucose positron-emission-tomography/computed tomography (18F-FDG PET/CT) is widely used for diagnosis and
staging of most cancers. We hypothesized that 18F-FDG PET/CT—especially if used early—is suitable for the detection of the
primary tumor in patients with CUP.
Objective: To assess the ability of 18F-FDG PET/CT to detect the primary tumor in adult CUP patients.
Data Sources: PubMed/Medline, Embase, and Web of Science.
Study Eligibility Criteria: Studies on CUP from extracervical metastases in which every patient had received an 18F-FDG PET/
CT scan and at least one 18F-FDG PET/CT-positive ﬁnding was conﬁrmed by biopsy or clinical follow-up.
Study Appraisal: PRISMA and QUADAS-2 were applied.
Synthesis Methods: The pooled detection rate (DR) of 18F-FDG PET/CT was assessed with a ﬁxed-effects model.
Heterogeneity among studies was assessed with the I-squared statistic.
Results: A total of 2953 articles were identiﬁed from which N=82 were assessed by full text and N=20, comprising 1942 adult
patients, were included in the study. Median (range) number of patients and DR was N=72 (21–316) and 36.3% (9.8%–75.3%),
respectively. Two-thirds of included studies were retrospective, and the pooled DR was 40.93% (95% conﬁdence interval:
38.99%–42.87%). There was large heterogeneity between studies (I-squared=95.9%), randomization was not applied, CUP
diagnosis was not standardized, and workup (if described) was characterized by multiple testing procedures resulting in a highly
selected, challenging patient group.
Conclusions: Despite great heterogeneity in diagnostic workup and in studies in general, an overall DR of 40.93% suggests that
upfront application of 18F-FDG PET/CT may have a role in CUP by obviating a great many futile diagnostic procedures. To what
degree 18F-FDG PET/CT used early in the course of disease may improve the detection rate could not be deducted from selected
articles. A large, prospective, preferably randomized, study on the potential beneﬁt of using 18F-FDG PET/CT up front in CUP
patients is warranted to judge if and when 18F-FDG PET/CT should be applied in these patients.
Abbreviations: 18F-FDG = 18-ﬂuorine-ﬂuorodeoxyglucose, CI = conﬁdence interval, CUP = cancer of unknown primary, DR =
detection rate, ES = estimate, FP = false positive, MeSH = medical subheadings, MRI = magnetic resonance imaging, PET/CT =
positron-emission-tomography/computed tomography, PICO = population intervention comparison outcome, PRISMA = preferred
reporting items for systematic reviews and meta-analysis, QUADAS = quality assessment of diagnostic accuracy studies, s.e. =
standard error.
Keywords:cancer, cancer detection, cancer of unknown primary, diagnosis, diagnostic imaging, meta-analysis, positron emission
tomography and computed tomography
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1. Introduction
Cancer of unknown primary (CUP) is a heterogeneous clinical
entity comprising patients presenting metastases of unknown
origin following conventional diagnostic workup procedures.
The prevalence of CUP (deﬁned as “unknown and ill-deﬁned
cancers”) in Denmark in 2009 to 2013 was 1042 patients which
accounts for 2.5% (men) and 3.2% (women) of all cancer
diagnoses in this period.[1] In the UK, the proportion of CUP
patients among all cancer cases was 3% in 2014,[2] and the
American Cancer Society estimated that about 33,770 cases of
CUP will be diagnosed in 2017 in the United States which
represents about 2% of all cancers.[3] Diagnostic investigations
are expensive and time consuming, and they may cause
discomfort to the patients. In 40% to 50% of CUP cases,
primary tumor is not found.[4] Patients have by deﬁnition
advanced illness at the time of diagnosis; generic (and usually less
effective) treatment regimen rather than speciﬁc ones have to be
employed when the origin of the cancer cannot be established
which in turn may contribute to an overall poor prognosis. The
relative 1-year survival (95% conﬁdence interval [95% CI]) in
Denmark was 38% (36%–40%) for men and 43% (41%–45%)
for women and the relative 5-year survival was 19% (17%–20%)
and 19% (18%–20%), respectively.[1]
Whole-body detection of tumor can be achieved with
18-ﬂuorine-ﬂuorodeoxyglucose positron-emission-tomography/
computed tomography (18F-FDG PET/CT).[5] The highmetabolic
turnover in cancer cells is exploited in the PET scan with the
use of a glucose analogue labeled with the radioactive isotope
ﬂuorine-18 as a tracer. Previously, studies have shown that
18F-FDG PET is effective in the diagnosis of many different
tumor types.[6] The relative nonspeciﬁcity of FDG may
pose a challenge although the addition of CT in combined
PET/CT scanners has greatly enhanced the assessment of positive
metabolic accumulation by adding the anatomical dimension.
PET/CT is recommended as an additional diagnostic tool if
primary tumor is not detected after conventional workup in
patients with CUP and cervical lymph node metastases.[7]
Evidence for patients with CUP and extracervical metastases
remains to be established.[8] The objective of this systematic
literature reviewwas to assess the potential role of 18F-FDGPET/
CT in the detection of the primary tumor in adult CUP patients
with extracervical metastases as judged from the available
literature.
2. Methods
The systematic review was done in accordance with the Preferred
Reporting Items for Systematic reviews and Meta-Analysis
(PRISMA) statement.[9] A review protocol does not exist. An
ethical review was not necessary due to the nature of this study.
2.1. Systematic literature search
The population, intervention, comparison, outcome (PICO)
framework[10] was applied to the research question “Do adult
patients with extracervical metastases from cancer of unknown
primary experience improved primary tumor detection by means
of 18F-FDG PET/CT compared with other diagnostic inves-
tigations?” The target population consisted of adult patients with
extracervical metastases from CUP. The intervention of the
diagnosing examination was molecular imaging with 18F-FDG
PET/CT which was compared with conventional diagnostic
investigations comprising a wide range of examinations like
laboratory tests, contrast enhanced CT, magnetic resonance
imaging (MRI), and pan-endoscopies for head and neck cancers.
Outcomemeasures were DR (deﬁned as positive PET/CT ﬁndings
of primary tumors conﬁrmed by biopsy or composite reference
standard including follow-up and other imaging modalities on a
per-patient basis) and FP proportion (deﬁned as proportion of
positive PET/CT ﬁndings that could not be conﬁrmed as primary
tumors by biopsy or other diagnostic procedures when a biopsy
could not be applied).
Three databases were searched: PubMed/Medline, Embase,
and Web of Science. For PubMed/Medline, the search
strategy comprised both free text search and usage of
Medical SubHeadings (MeSH). For Embase, free text search
and the Emtree Thesaurus were used. The search was
conducted on April 4, 2016 using the following search terms
and their derivatives: cancer of unknown primary, positron
emission tomography/computed tomography, and 18F-FDG.
Neither date nor language limits were applied. A full search
strategy is provided as Supplemental Digital Content 1,
http://links.lww.com/MD/B669. All search results were
collected, merged, and ﬁltered with EndNote X7 (Thomson
Reuters, Philadelphia, PA).
2.2. Selection of literature
One author (SAB) screened titles and abstracts and consulted a
second reader (SH) in case of equivocal papers. Another reader
(OG) independently assessed full-text articles for eligibility;
disagreement was dissolved by consensus between all 3 readers.
Inclusion criteria were as follows:
– Original studies on cancer of unknown primary from
extracervical metastases.
– Every patient in the population had to have received an
18F-FDG PET/CT scan.
– At least 1 positive 18F-FDG PET/CT ﬁnding (i.e., lesion) had to
be conﬁrmed by biopsy to validate it as being primary tumor;
alternatively, a composite reference standard including clinical
follow-up and other imaging procedures was applied.
– Access to numbers of: the total number of patients who had an
18F-FDG PET/CT scan, the number of positive ﬁndings that
were conﬁrmed as well as the total number of positive ﬁndings
which were not conﬁrmed by pathology to calculate DR and FP
if not stated by the authors.
Exclusion criteria were the following:
– Studies that included patients with a previous cancer.
– Studies that included patients who already received treatment
for their current cancer.
– Studies with a population of both known and unknown
primaries.
2.3. Data extraction
The deﬁnition of DR was the number of patients with positive
PET/CT ﬁndings which were conﬁrmed by biopsy or composite
reference standard including follow-up and other imaging
modalities, divided by the total number of patients included.
The reported DR was taken as published if the above-mentioned
deﬁnition was met; if other deﬁnitions of DR were used, we
recalculated the DR according to the above-mentioned deﬁnition.
The number of false-positive ﬁndings was extracted and used to
assess its relative frequency in the study (FP proportion). All data
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were extracted by 1 author (SAB). Data on the primary endpoint
DR was independently extracted for validation purposes by
another author (OG). Details on included studies were listed.
2.4. Statistical analysis
Descriptive statistics were used according to datatype; continu-
ous variables were analyzed by medians and ranges, whereas
categorical variables were displayed by means of absolute and
relative frequencies by study. When comparing DR and FP
proportion across studies, median values and ranges were
reported. DR was also meta-analyzed with a ﬁxed-effects model
using the inverse variance method. A Forest plot[11] and a Funnel
plot[12–15] were derived to graphically display the point estimate
and a respective 95%CI for DR on a per-study basis, graphically
display the summary estimate for DR (incl. its 95% CI) across
studies, derive ameasure for the heterogeneity of the studies (incl.
an I2 value[16]), and assess publication bias visually. All analyses
were done by using STATA/MP 14.2 (StataCorp, College
Station, TX).
2.5. Quality assessment
Possible sources for bias were assessed with the Quality
Assessment of Diagnostic Accuracy Studies (QUADAS) tool.[17]
Accordingly, 4 domains were evaluated for each study (patient
selection; index test; reference standard; ﬂow and timing), with 2
to 3 signaling questions in each domain. If all signaling questions
within a domain could be answered with “yes,” a low risk of bias
was indicated for that domain. If any signaling question for a
domain could be answered with “no” or “unclear” due to lack of
details, bias potentially existed.
3. Results
3.1. Literature search
The sum of results from 3 databases was 2953 (Fig. 1). Doublets
and foreign language articles other than English, Danish, or
Norwegian were excluded (N=933). Thus, 2020 were available
for screening by title/abstract. This screening led to exclusion of
1938 records: case reports (N=284), congress/meeting abstracts
Records identified through database 
search  
(n = 2953) 
Sc
re
en
in
g  
In
cl
ud
ed
 
E
lig
ib
ili
ty
 
Id
en
tif
ic
at
io
n 
Records after removal of duplicates and 
language restriction to English, Danish, and 
Norwegian (n = 2020) 
Records screened  
(n = 2020) 
Records excluded 
(Case reports, reviews, conference papers, 
other focus) 
(n = 1938) 
Full-text articles assessed 
for eligibility  
(n = 82) 
Full-text articles excluded 
(n = 62) 
Cervical metastases (30) 
Extracervical metastases indicated 
by PET alone (no PET/CT scan) 
(11) 
Case series (2) 
Former cancer in population (1) 
Insufficient reference standard (5) 
Non-CUP/Staging study (5) 
Only part of population had a 
PET/CT scan (5) 
Opinion paper (1) 
Quantification study (2) 
 
Studies included in 
qualitative synthesis  
(n = 20) 
Figure 1. PRISMA ﬂow chart.[9]
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(N=124), editorials/letters (N=23), reviews/textbook pages
(N=204), additional doublets and language mismatches (N=
128), and studies with another focus (N=1175). The remaining
82 papers were assessed by full-text reading and the above-
mentioned inclusion/exclusion criteria were applied. Thirty
studies were excluded as these focused on cervical metastases,
and further 11 studies did actually investigate extracervical
metastases, but did so using PET alone (i.e., without CT).
Moreover, 21 articles were excluded because of analyzing case
series (N=2), including former cancer in population (N=1),
using insufﬁcient reference standard (N=5), being non-CUP or
staging study (N=5), comprising patient groups which only
partly received a PET/CT scan (N=5), being an opinion paper
(N=1), and aiming at quantiﬁcation of disease (N=2). The
remaining 20 studies were included into this study.[18–37]
3.2. Study and patient characteristics
The included studies were reported between 2005 and 2016 and
comprised 1942 patients. Thirteen studies (65%) were retro-
spective, 4 (20%) prospective, and 3 (15%) unclear (Table 1).
Median number of patients wasN=72 (range: 21–316).Mean or
median age of patients was around 60 years for most studies and
respective age ranges within the studies covered often close to
whole adulthood. Seventeen of 20 studies included more men
than women (median proportion of males: 57.9%).
Diagnostic workup prior to 18F-FDG PET/CT comprised a
variety of diagnostic imaging procedures that included, for
instance, CT alone, MRI, mammography, ultrasound, and
physical examination. Tumor mass was often spread widely
across the body in most studies (Supplemental Digital Content 2,
http://links.lww.com/MD/B669). Details on 18F-FDG PET/CT
imaging in the included studies (dosage, use of contrast
enhancement, and area of scan) can be found in Supplemental
Digital Content 3, http://links.lww.com/MD/B669.
3.3. Diagnostic performance on PET/CT
The median DR was 36.3% (range: 9.8%–75.3%; Table 2). The
pooled DR with (95% CI) was 40.93% (38.99%–42.87%) with
an I2 of 95.9% (Fig. 2), the latter indicating large heterogeneity
between studies. The respective Funnel plot was roughly
symmetrical, but the 5 studies with the lowest detection
rates[20,27,29,30,33] aswell as the 2 studies with the highest detection
rates[19,28] were outside the funnel, possibly indicating publication
bias (Supplemental Digital Content 4, http://links.lww.com/MD/
B669). The median FP proportion was 7.5% (range
2.3%–22.2%). Results from 3 studies[24,31,36] were restricted to
a subgroup of patients to match our inclusion criteria.
3.4. Quality assessment
The quality assessment with QUADAS[17] indicated an overall
low risk of bias across studies with respect to patient selection and
reference standard, whereas risk of bias was assessed high in 6 of
20 studies (30%) regarding ﬂow and timing and unclear in 12 of
20 studies (60%) regarding the index test (Fig. 3, based on
Supplemental Digital Content 5, http://links.lww.com/MD/B669).
With respect to the applicability of patient selection and reference
standard, around 2 of 3 of the included studies suggested low
concerns, but 11 of 20 studies (55%) suggested an unclear
applicability of the index test.
4. Discussion
In this study, a comprehensive literature search was conducted to
establish the current evidence for the use of PET/CT in adult
Table 1
Study and patient characteristics.
Study Year Study design N Age in years, mean±SD (range) or median (range) Gender (M/F)
Yaylali[18] 2016 Retrospective 50 61.64±16.26 (18–85) 29/21
Jain[19] 2015 Prospective 163 NR (30–70) 102/61
Breuer[20] 2014 Retrospective 70 61.6±NR (38–81) 37/33
Elboga[21] 2014 Retrospective 112 60.5 (24–90) 72/40
Barbosa[22] 2013 NR 89 57.17±11.8 (30–89) 77/12
Deonarine[23] 2013 Retrospective 51 65 (30–87) 20/31
Saidha[24] 2013 Prospective 50
∗
56.5jj (26–76) 31/19
Wang[25] 2013 Retrospective 142 56 (13–89) 93/52
Han[26] 2012 Retrospective 120 NR (28–72) 66/54
Møller[27] 2012 Prospective 135 62 (32–81) 65/70
Tamam[28] 2012 Retrospective 316 NR 186/130
Hu[29] 2011 Retrospective 149 59 (32–75) 84/65
Pak[30] 2011 Retrospective 51 58.7±12.55 32/19
Yapar[31] 2010 NR 90† 55.86±14.11 (22–84) 60/30
Kaya[32] 2008 Retrospective 43 50 (37–76) 32/11
Fencl[33] 2007 Retrospective 190 59 (6–88) 81/109
Ambrosini[34] 2006 NR 38‡ 59±11 (41–77) 22/16
Pelosi[35] 2006 Retrospective 68 63±NR (42–79) 36/32
Gutzeit[36] 2005 Retrospective 45x 60jj (26–95) 26/19
Nanni[37] 2005 Prospective 21 63jj (41–87) 12/9
NR=not registered.
∗
Only 34 out of 50 patients belonged to group 1 (extracervical metastases).
† Only 74 out of 90 patients had histologically proven metastatic lesions.
‡ One patient had larynx cancer.
x Only 27 out of 45 patients had extracervical metastases.
jj Calculated from data of Table 1 of respective paper.
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patients with CUP with special reference to DR and false-positive
ﬁndings in patients with extracervical metastases. We identiﬁed
20 studies with an overall DR of 40.93% (95% CI:
38.99%–42.87%); median DR and median FP proportion were
36.3% and 7.5%, respectively.
This study’s strength is the extensive literature search that
identiﬁed 2953 potential articles, and its ﬁndings are based on
1942 patients. Moreover, the PICO framework, the PRISMA
statement, and the QUADAS tool were applied. The selection of
full-text articles (N=82) to be assessed was done by only 1 author
(SAB), and this screening process could have been strengthened
by having 2 readers independently assess all potential articles.
Concerning the selection of relevant literature, only original full
papers were included, excluding, for instance, conference
abstracts with the potential risk of missing recent unpublished
work.
Table 2
Diagnostic performance of PET/CT.
Study Year Primary tumor detection rate (DR) False-positive proportion
Yaylali[18] 2016 16/50 32% 6/50 12%
Jain[19] 2015 113/163 69.3% 15/163 9.2%
Breuer[20] 2014 17/70 24.3% 3/70 4.3%
Elboga[21] 2014 37/112 33% 21/112 18.8%
Barbosa[22] 2013 29/89 32.6% 6/89 6.7%
Deonarine[23] 2013 19/51 37.3% 8/51 15.7%
Saidha[24] 2013 13/34 38.2% 1/34 2.9%
Wang[25] 2013 67/142 47.2% 6/142 4.2%
Han[26] 2012 54/120 45% 9/120 7.5%
Møller[27] 2012 38/135 28.1% 30/135 22.2%
Tamam[28] 2012 238/316 75.3% 12/316 3.8%
Hu[29] 2011 37/149 24.8% 13/149 8.7%
Pak[30] 2011 5/51 9.8% 9/51 17.6%
Yapar[31] 2010 32/74 43.2% 7/74 9.5%
Kaya[32] 2008 24/43 55.8% 1/43 2.3%
Fencl[33] 2007 31/190 16.3% 26/190 13.7%
Ambrosini[34] 2006 19/37 51.4% 1/37 2.7%
Pelosi[35] 2006 24/68 35.3% 5/68 7.4%
Gutzeit[36] 2005 9/27 33.3% 2/27 7.4%
Nanni[37] 2005 12/21 57.1% NR
NR=not registered, PET/CT = positron-emission-tomography/computed tomography.
Figure 2. Forest plot on DR. CI=conﬁdence interval, DR=detection rate, ES=estimate.
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It is clear from the study characteristics (Table 1, Supplemental
Digital Content 2 and 3, http://links.lww.com/MD/B669) that the
evidence of PET/CT as a diagnostic tool in CUP is challenged by a
signiﬁcant heterogeneity among included studies (see also I2=
95.9% and Fig. 2 and Supplemental Digital Content 4, http://
links.lww.com/MD/B669). First, a majority of studies were
retrospective (65%), only 20%were prospective, and none of the
included studies employed randomization. Second, the patient
populations varied widely ranging from 20 to 316 with a median
of 72. Third, the deﬁnition in CUP as a diagnosis was not
standardized; most studies had biopsy-veriﬁed metastases as an
inclusion criterion, but some studies also included patients with
“clinical suspicion of malignancy.”[25,28,31]
Along the same lines, the deﬁnition of “standardized diagnostic
workup” prior to PET/CT scans was also not standardized.
Available details of diagnostic strategy varied from no registra-
tion[19,31,33] to presentation of speciﬁc investigations and the
number of patients receiving each examination.[26,27,30] Based on
studies where diagnostic work-up regimens were presented, many
patients underwent a signiﬁcant array of diagnostic tests, both
invasive and noninvasive. This has 2-fold consequences: patients
included are highly selected toward the difﬁcult ones since
obvious diagnosis will be made in many instances from the
standard workup; and the number of unnecessary or futile
procedures may be overwhelming to individual patients. This
may in turn lead to delayed diagnosis, adverse effects from
invasive procedures, and increased health care costs.
Another matter is the reference standard. Applying a relevant
and accurate reference standard is pivotal in diagnostic accuracy
studies, preferably histopathology. Due to our inclusion criteria,
all included studies used histology as reference standard to some
extent, but when inconclusive or not available, several studies
also accepted other diagnostic procedures and investigations,
e.g., other imaging, endoscopies, or clinical follow-up. Only in a
few of the studies, the information provided allowed us to
determine the separate reference standard on a per-patient
basis.[25–27,29,30] In these studies, we accepted the reference
standard including clinical follow-up (or other imaging during
follow-up) as reference standard to provide an improved
standard of comparison.
Prior studies have shown similar detection rates in CUP
patients. Dong et al[38] extracted 28 studies (comprising 910
patients) published between 1990 and 2007. In 8 of these studies
(5 were retrospective and 3 were prospective), 430 patients with
CUPwere diagnosed by 18F-FDG PET/CT, and 31.4% (N=135)
of the primary tumors were detected. Pooled sensitivity and
speciﬁcity were 0.81 (95% CI: 0.74–0.87) and 0.83 (95% CI:
0.78–0.87), respectively. Kwee and Kwee[39] included 11 studies
(8 retrospective, 3 unclear), comprising a total sample size of 433
patients with CUP, and found an overall primary tumor detection
rate, a pooled sensitivity and speciﬁcity of 18F-FDG PET/CT of
37%, 84% (95% CI: 78–88%) and 84% (95% CI 78–89%).
Similarly, the systematic review by Møller et al[8] on 4
retrospective studies found that 18F-FDG PET/CT detected the
primary tumor in 39.5% of patients with extracervical CUP; the
pooled sensitivity, speciﬁcity, and accuracy of 18F-FDG PET/CT
in the detection of the primary tumor site were 87%, 88%, and
87.5%, respectively. All studies included by Møller et al[8] were
also included here,[31,34–36] whereas we included only 5 of 11
studies used by Kwee and Kwee[39] and 5 of 8 studies used by
Dong et al,[38] namely.[33–37] All 3 meta-analyses[8,38,39] were
affected by large heterogeneity between studies. The authors
concluded that prospective studies are warranted to investigate
the assumed advantage of 18F-FDG PET/CT over 18F-FDG PET
alone and to explore causes of heterogeneity[39] and should
employ more uniform inclusion criteria to evaluate the exact
value of 18F-FDG PET/CT as a diagnostic tool in CUP patients
with extracervical metastases.[8]
Finally, there is a special issue when assessing the usefulness of
PET in CUP, an issue that most existing literature did not
consider, namely the fact that by the very nature of disease PET is
useful for the detection of the primary only when applied early in
0 20 40 60 80 100
Proportion of studies with low, high, or unclear risk of bias, %
Patient selection
Index test
Reference standard
Flow and timing
Low High Unclear
0 20 40 60 80 100
Proportion of studies with low, high, or unclear concerns regarding applicability, %
Patient selection
Index test
Reference standard
Figure 3. Graphical display of QUADAS results.[17] QUADAS = quality assessment of diagnostic accuracy studies.
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the course of disease. As soon as more than a few suspicious foci
have developed, it becomes increasingly difﬁcult for PET to point
to a potential primary tumor the more lesions have become
visible. These cases will paradoxically count as “false negatives”
despite the fact that PET does actually “see” something and
would probably have had a fair chance to detect the primary
tumor had the patient come earlier to PET imaging. From the
existing literature it was not possible to estimate how often this
situation handicapped the performance of PET/CT.
CUP patients have per deﬁnition advanced illness and will
typically receive a generic rather than a speciﬁc (and possibly
more effective) treatment if the origin cannot be established.
This leads to a poorer prognosis and, thus, establishing the
underlying primary is pivotal to ensure timely and effective
treatment. Standard diagnostic workup is heterogeneous and
often comprises a multitude of more or less invasive procedures.
An accurate single modality is therefore in high demand and 18F-
FDG PET/CT has shown promising results in this regard; it is
likely to be most valuable, the earlier in the course it is used,
instead of, as in most cited studies, being applied late and
sometimes as a last option. The missing link is a comprehensive
prospective, randomized trial with up-front 18F-FDG PET/CT as
the ﬁrst line modality in 1 study arm and conventional
diagnostic workup in the other arm. One challenge will be
the formulation of appropriate inclusion and exclusion criteria
to be speciﬁc enough to include only CUP patients and not
another important, but much larger, group, namely patients
with serious nonspeciﬁc symptoms or signs without any biopsy
evidence of cancer.
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